The supply of Ig in France has been in regular tension for several years. The National Medicines and Health Products Safety Agency (HPSA) and supervisory bodies such as the Directorate General of Health (DGH) have noted these difficulties. A hierarchy of indications for Ig has therefore been developed in collaboration with healthcare professionals such as physicians, pharmacists and patient associations concerned, in order to prioritize the use of Ig for patients without therapeutic alternatives.

However, these tensions are perpetuated at the global level and are accentuated by the pandemic linked to COVID 19 due to the scarcity of plasma donations, the latter being collected mainly in the United States and in some countries of the European Union.

For more information, please find attached the letter co-signed by CEREDIH, IRIS and PERMEDES concerning the persistent tensions in the supply of immunoglobulins in patients with Hereditary Immune Deficits